ReviewTheranostics2017
Bioengineering of Artificial Antigen Presenting Cells and Lymphoid Organs.
Review in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Focused ultrasound for cellular mechanoactivation and nanomedicine delivery in cancer.Biomedical microdevices · 2026Review
- Self-propelled platinum based magnetite Janus nanomotors prepared from PCL and PHEMA graft copolymer with physicochemical properties motility and peroxidase-like activity.Scientific reports · 2026Article
- Cancer immunotherapy strategies based on transition‑metal medical materials: Still a long way to go (Review).International journal of oncology · 2026Review
- Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives.Molecular cancer · 2025Review
- Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells.Cellular and molecular life sciences : CMLS · 2024Review
- Advances in nano-immunotherapy for hematological malignancies.Experimental hematology & oncology · 2024Review
- Lymph node-biomimetic scaffold boosts CAR-T therapy against solid tumor.National science review · 2024Article
- Organismal Function Enhancement through Biomaterial Intervention.Nanomaterials (Basel, Switzerland) · 2024Review
- Precise surface functionalization of PLGA particles for human T cell modulation.Nature protocols · 2023Article
- Cell-Sized Lipid Vesicles as Artificial Antigen-Presenting Cells for Antigen-Specific T Cell Activation.Advanced healthcare materials · 2023Article
- Cell therapy biomanufacturing: integrating biomaterial and flow-based membrane technologies for production of engineered T-cells.Advanced materials technologies · 2023Article
- T cell-responsive macroporous hydrogels for in situ T cell expansion and enhanced antitumor efficacy.Biomaterials · 2023Article
- Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy.Science advances · 2022Review
- Biomimetic and Materials-Potentiated Cell Engineering for Cancer Immunotherapy.Pharmaceutics · 2022Review
- Platelet transfusion for cancer secondary thrombocytopenia: Platelet and cancer cell interaction.Translational oncology · 2021Review
- Chemically Engineered Immune Cell-Derived Microrobots and Biomimetic Nanoparticles: Emerging Biodiagnostic and Therapeutic Tools.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Investigation of the Immune Modulatory Potential of Zinc Oxide Nanoparticles in Human Lymphocytes.Nanomaterials (Basel, Switzerland) · 2021Article
- Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection.Advanced drug delivery reviews · 2021Review
- Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy.Biomaterials · 2021Review
- Emerging nanomedicines for effective breast cancer immunotherapy.Journal of nanobiotechnology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immune system protects the body against a wide range of infectious diseases and cancer by leveraging the efficiency of immune cells and lymphoid organs. Over the past decade, immune cell/organ therapies based on the manipulation, infusion, and implantation of autologous or allogeneic immune cells/organs into patients have been widely tested and have made great progress in clinical applications. Despite these advances, therapy with natural immune cells or lymphoid organs is relatively expensive and time-consuming. Alternatively, biomimetic materials and strategies have been applied to develop artificial immune cells and lymphoid organs, which have attracted considerable attentions. In this review, we survey the latest studies on engineering biomimetic materials for immunotherapy, focusing on the perspectives of bioengineering artificial antigen presenting cells and lymphoid organs. The opportunities and challenges of this field are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.